ECSP11011550A - Procedimientos de uso del factor liberador de corticotropina para eltratamiento de cáncer - Google Patents

Procedimientos de uso del factor liberador de corticotropina para eltratamiento de cáncer

Info

Publication number
ECSP11011550A
ECSP11011550A ECSP11011550A ECSP11011550A EC SP11011550 A ECSP11011550 A EC SP11011550A EC SP11011550 A ECSP11011550 A EC SP11011550A EC SP11011550 A ECSP11011550 A EC SP11011550A
Authority
EC
Ecuador
Prior art keywords
procedures
cancer treatment
release factor
corticotropine
corticotropine release
Prior art date
Application number
Other languages
English (en)
Inventor
Evans Freke Stephen
Original Assignee
Evans Freke Stephen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43243708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011550(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Evans Freke Stephen filed Critical Evans Freke Stephen
Publication of ECSP11011550A publication Critical patent/ECSP11011550A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan en el presente documento procedimientos para tratar cáncer en un ser humano mediante la administración de CRF, opcionalmente en combinación con un segundo agente, tal como un inhibidor de angiogénesis.
ECSP11011550 2009-06-24 2011-12-23 Procedimientos de uso del factor liberador de corticotropina para eltratamiento de cáncer ECSP11011550A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22005509P 2009-06-24 2009-06-24

Publications (1)

Publication Number Publication Date
ECSP11011550A true ECSP11011550A (es) 2012-04-30

Family

ID=43243708

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP11011550 ECSP11011550A (es) 2009-06-24 2011-12-23 Procedimientos de uso del factor liberador de corticotropina para eltratamiento de cáncer

Country Status (20)

Country Link
US (1) US20120183536A1 (es)
EP (1) EP2349323A2 (es)
JP (1) JP2012530740A (es)
KR (1) KR20120124353A (es)
CN (1) CN102481342A (es)
AU (1) AU2010265081A1 (es)
BR (1) BRPI1012262A2 (es)
CA (1) CA2766322A1 (es)
CL (1) CL2011003248A1 (es)
CO (1) CO6480929A2 (es)
CR (1) CR20110687A (es)
EC (1) ECSP11011550A (es)
IL (1) IL216930A0 (es)
MX (1) MX2012000203A (es)
NI (1) NI201100228A (es)
PE (1) PE20120559A1 (es)
RU (1) RU2012102259A (es)
SG (1) SG176802A1 (es)
WO (1) WO2010149357A2 (es)
ZA (1) ZA201109508B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3679934B1 (en) * 2011-04-29 2024-06-05 The Penn State Research Foundation Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
US10697023B2 (en) 2015-05-05 2020-06-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Systems and methods for providing personalized radiation therapy
CN110545820B (zh) * 2017-04-06 2023-01-10 沈阳福洋医药科技有限公司 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用
CN110384710B (zh) * 2018-04-17 2023-01-10 沈阳福洋医药科技有限公司 一种用于预防和/或治疗疼痛的药物、组合产品及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415558A (en) 1981-06-08 1983-11-15 The Salk Institute For Biological Studies CRF And analogs
DE3209645A1 (de) 1982-03-17 1983-09-29 Dr.Ing.H.C. F. Porsche Ag, 7000 Stuttgart Vorrichtung zum regeln einer kraftfahrzeug-antriebseinheit
EP0120000A1 (en) 1982-09-29 1984-10-03 LEDERIS, Karl P. Urotensin peptides
US4528189A (en) 1983-02-03 1985-07-09 The Salk Institute For Biological Studies Urotensin peptides
US4489163A (en) 1983-04-14 1984-12-18 The Salk Institute For Biological Studies rCRF and analogs
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
AU2009241813A1 (en) * 2008-04-30 2009-11-05 Neutron Row Methods of using corticotropin-releasing factor for the treatment of cancer
WO2010057962A2 (en) * 2008-11-19 2010-05-27 Neutron Limited Crf conjugates with extended half-lives

Also Published As

Publication number Publication date
CR20110687A (es) 2012-05-18
WO2010149357A2 (en) 2010-12-29
NI201100228A (es) 2012-05-23
JP2012530740A (ja) 2012-12-06
ZA201109508B (en) 2013-05-29
US20120183536A1 (en) 2012-07-19
MX2012000203A (es) 2012-04-20
AU2010265081A1 (en) 2012-01-19
WO2010149357A3 (en) 2011-06-16
CL2011003248A1 (es) 2012-04-13
SG176802A1 (en) 2012-01-30
IL216930A0 (en) 2012-02-29
EP2349323A2 (en) 2011-08-03
BRPI1012262A2 (pt) 2016-04-05
CO6480929A2 (es) 2012-07-16
CN102481342A (zh) 2012-05-30
KR20120124353A (ko) 2012-11-13
CA2766322A1 (en) 2010-12-29
PE20120559A1 (es) 2012-05-21
RU2012102259A (ru) 2013-07-27

Similar Documents

Publication Publication Date Title
CU20120042A7 (es) (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
GT201200123A (es) Nuevo uso antitumoral de cabazitaxel
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
CL2017001943A1 (es) Terapias de combinación para el tratamiento de cánceres
CL2012002037A1 (es) Uso de agonista doble del glucagon-glp-1 como agente inotropico en el tratamiento de la cardiopatía o la disfuncion cardiaca
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
CL2012001405A1 (es) Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer.
AR089252A1 (es) Conjugados de principio activo-ligante (adc) y su uso
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
CR20110553A (es) Terapia complementaria contra el cáncer
GT201300260A (es) Composición que comprende aflibercept, ácido folínico, 5-fluorouracilo (5-fu) e irinocetan (folfiri)
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
GT201500071A (es) Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3
MX2011011596A (es) Perifosina y capecitabina como un tratamiento combinado para cancer.
CO6761366A2 (es) Composiciones farmacéuticas para el tratamiento de glioma maligno
CO6351779A2 (es) Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos
CO6741197A2 (es) Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma
ECSP11011550A (es) Procedimientos de uso del factor liberador de corticotropina para eltratamiento de cáncer
CO6731081A2 (es) Método para producir y usar un copolímero de carboximetilcelulosa sódica y gosipol
CR20150148A (es) Azaindolinas
CR20120166A (es) Composiciones y productos antimicrobianos
UY35033A (es) Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
AR092169A1 (es) Composicion farmaceutica sinergica adaptada para ser administrable oralmente como antiparasitario y procesos para prepararla